Chinese Bio Revolution: Cause for concern?  Patient Benefits and a Bigger Pie for Everyone.

China has become one of the most important forces in global BioPharma.

For many Western companies, this development can still feel difficult to interpret. Some may view China primarily as a competitive threat. Others might see it as a complex market that is hard to access, hard to understand, and sometimes difficult to trust from the outside. However, framing China solely in terms of competition seems a bit narrow and risks missing the opportunities it presents for innovation, collaboration, and improved patient outcomes. After all, there’s a saying that in a crisis there can be both danger and opportunity. While the Chinese language doesn’t literally combine risk and opportunity in one word, the idea resonates: where others see threats, there can also be openings for innovation, growth, and patient benefit.

Rather than viewing the rise of the Chinese BioPharma industry simply as an us versus them question, it helps to see how investors, innovators, and patients can benefit from a larger pool of scientific progress. Growth is happening whether individual companies, investors, or other stakeholders plan to participate or not. Historically, China might have mostly produced me too assets, but today they are innovating at an impressive pace. Just looking at the ADC field, most of the assets now come from China.

Most multinational companies, if not all, have done deals with Chinese companies. There are various hub and spoke VCs taking advantage of what might be conceived as a mispricing of certain assets due to capital constraints. To me personally, this represents a significant opportunity for companies to help bring better treatments to patients.

A Decade of Growth in Clinical Trials

Over the last ten years, we have seen dramatic growth in China’s clinical trial activity.

In 2011, there were roughly 57 Phase I clinical trials registered in China, reflecting the early stages of domestic innovation. By 2020, that number had increased more than tenfold to 601 Phase I trials, reflecting an average annual growth rate of ~37 percent in early stage clinical research. By 2023, China recorded over 4,300 clinical trials, including more than 2,300 trials for new drug candidates, the highest annual total ever registered. More than half of these trials focused on innovative, unapproved drug candidates, signaling a strong shift toward original research rather than incremental improvements or generics.

This is not just volume. Chinese companies are increasingly running trials in novel indications and newer modalities. These studies are accelerating innovation, contributing to a rapid increase in first approvals, and generating earlier and more robust signals in Phase I and II that can improve later stage decision making. Broad early stage recruitment may help de risk Phase III programs and accelerate development timelines. This means that China is not only producing more trials, but the trials themselves are increasingly sophisticated and globally relevant.

This data shows that Chinese companies are scaling quickly and producing a significant portion of early stage innovation that could shape the global BioPharma landscape. Early phase clinical trial activity is a leading indicator of long term innovation capacity, and China’s growth in this area is remarkable.

Speed and Execution

One illustrative comparison comes from the automotive industry. I believe it was Jacob Wallenberg who, during an appearance on a Swedish finance channel, highlighted that in China, new car models are launched roughly every two years, compared to five years in the US and seven years in the EU. While the statistics may not translate exactly to BioPharma, the point about China’s faster innovation cycles remains valid.

Similarly, Chinese biotechs are developing assets more rapidly, generating clinical data faster and cheaper, building stronger discovery platforms, and becoming increasingly active in global business development and licensing. From early discovery to clinical execution, speed and scale have become distinguishing features of the Chinese ecosystem.

Something that comes to mind here is the art of repetition and practice, much like when writing and reading: “repetition is the mother of all skill.” There was an experiment where people were asked to make pottery. One group tried to make a perfect piece, while the other group simply made as many as possible. The latter ended up producing better results due to repetition and practice.

A Larger Pie, Not Zero Sum Competition

Another perspective is to consider the larger pie. Rather than viewing Chinese growth as a threat that takes market share, it can also be seen as a considerable expansion of the global market. Increased activity in China does not inherently reduce opportunities for Western companies. On the contrary, it opens new avenues for licensing, co development, partnerships, and collaboration, allowing all players to innovate, expand their reach, and ultimately benefit patients.

Western companies still bring significant strengths: regulatory expertise, established global commercialization networks, brand credibility, and late stage clinical experience. Chinese companies offer complementary strengths: speed, cost efficiency, platform depth, and an increasingly robust pipeline of innovative assets. When structured effectively, partnerships can unlock value for both sides.

Many Chinese companies are open to doing business if others are willing to engage seriously. They are actively seeking international partnerships, licensing arrangements, co development structures, and commercial collaborations. Companies that are willing to understand the landscape and participate intelligently are most likely to benefit from these opportunities.

It is also worth noting the sheer size of the Chinese market across multiple indications, which creates additional scale and potential for collaboration that can benefit global stakeholders.

Patients Do Not Care About the Country of Origin

As someone whose family has faced cancer and other serious diseases, I believe that, in the end, it is about the patients. Patients care about receiving the most effective treatment, regardless of whether it comes from China, Europe, or the US. The origin of the therapy should not determine its value. Innovation should not be constrained by geography, whether the company is EU, US, or Asia based, regardless of funding, regulatory expertise, or capabilities. At the end of the day, it is about supporting innovation and creating treatments that can meaningfully benefit patients.

Growth Should Not Be Seen as Zero Sum

Chinese companies, like any others, have a legitimate right to growth and increased prosperity. Their rise does not automatically mean the decline of Western players. Instead, the focus should be on how to grow together. By leveraging complementary strengths in innovation, commercialization, regulatory strategy, and market access, both Western and Chinese companies can benefit.

This is not merely theoretical. Some of the most compelling opportunities in global BioPharma involve cross border collaboration. Licensing, co development, joint ventures, and regional partnerships are practical ways to ensure innovation is rewarded while reaching more patients. Seeing China’s rise as an opportunity rather than a threat enables the entire ecosystem to expand.

Economics and the IRR Challenge

Another part of this story is the economics of pharmaceutical R&D. If the internal rate of return on pharma R&D falls below the cost of capital, innovation does not stop, but it becomes much harder to sustain at the same speed and scale. Low returns mean companies become more cautious, capital allocation becomes selective, and internal discovery may slow. In contrast, China’s lower cost structure, faster clinical execution, and growing infrastructure allow companies to accelerate trial activity and approvals at a pace the West struggles to match.

This does not mean the US or Europe cannot remain leaders in BioPharma. They still have enormous strengths in science, regulation, commercialization, and capital formation. But the reality is that China’s rise is not only about volume, it is also about speed, economics, and innovation intensity.

Summary

China’s rise in BioPharma is impressive and interesting. It should neither be romanticized nor dismissed. There will be challenges, including regulatory, commercial, and cultural hurdles. But there are also opportunities: faster innovation cycles, robust clinical trial activity, increasing novel indications, more first approvals, and a growing willingness among Chinese companies to collaborate internationally.

The question is not whether China should be feared. The question is whether the industry will engage intelligently, build trust, and create structures that allow innovation to reach more patients.

At Jarlen Capital, we believe BioPharma should be evaluated based on scientific quality, strength of data, partner credibility, and patient benefit, not geography. The Chinese Bio Revolution is here. The choice is whether the industry sees only the fire or also the opportunity to grow together, expand possibilities, and ultimately improve patient outcomes.